Phase III COMMIT Study Shows Promising Frontline Approach for dMMR/MSI-H Metastatic Colorectal Cancer
The phase III COMMIT trial demonstrates that intensifying first-line immunotherapy with chemotherapy and antiangiogenic therapy can substantially improve outcomes for patients with deficient mismatch repair...
